tiprankstipranks
AnaptysBio sinks 30% after Lilly slides show PD-1 agonist pulled
The Fly

AnaptysBio sinks 30% after Lilly slides show PD-1 agonist pulled

Shares of AnaptysBio (ANAB) are plummeting after earnings slides from Eli Lilly (LLY) showed the company removed peresolimab, a PD-1 agonist, from its mid-stage pipeline. AnaptysBio is developing its own PD-1 agonist, rosnilimab. The shares in premarket trading are down 31%, or $9.44, to $21.69.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App